Printer Friendly

Integrated BioPharma announces National Science Foundation award. (Industry News).

The National Science Foundation has awarded funding for a Small Business Innovative Research proposal titled, "Regulated Expression of Therapeutic Proteins in Transgenic Brassica Plants" to Integrated BioPharma, Hillside, NJ. The proposal was prepared and submitted by NuCycle Therapy, a wholly owned subsidiary of Integrated BioPharma. The scientists plan to introduce the gene encoding human alpha interferon into Brassica, an edible crop plant, using a novel and proprietary gene transfer method. The GMO plants can then be grown in an environmentally safe way and used as an inexpensive source of human alpha interferon. Interferon is used to treat diseases such as chronic hepatitis and AIDS-related diseases, and a less expensive source of this drug has worldwide health benefits.
COPYRIGHT 2003 Rodman Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:to subsidiary NuCycle Therapy
Publication:Nutraceuticals World
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 1, 2003
Previous Article:Gelita establishes new names. (Industry News).
Next Article:Delivering products that stand out: examining how to position and sell nutraceutical products based on other market successes. (Strategy Sketchbook).

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |